Future Techly

Excited to share my latest article on ByteDance's OmniHuman AI! Discover how this groundbreaking technology transforms a single image into lifelike human videos, revolutionizing digital media and beyond. Dive in to explore its innovative features, real-world applications, and the future of AI-driven content creation. 🚀🤖 #AI #Innovation #DigitalMedia #ByteDance #OmniHumanAI

Yampa just raised €3M to revolutionize AI-powered customer service. Here’s how this Paris-based startup is transforming the way businesses interact with their customers ⬇️ Customer service is evolving. AI is no longer just a support tool—it’s becoming the front line. With Yampa’s autonomous AI agents, businesses can: ➡️ Offer 24/7 customer support across calls, emails, and chatbots. ➡️ Improve service quality while reducing operational costs. ➡️ Free up human agents for more complex, high-value tasks. Without AI-driven automation... Companies risk overwhelmed support teams, frustrated customers, and rising costs. That’s why Yampa is stepping in. With a fresh €3M Seed round led by Partech, alongside investors like Arthur Waller (Pennylane) and Guillaume D. (Alma), Yampa is set to accelerate its impact. What makes Yampa different? 1️⃣ Native, multichannel AI agents 🤖 ↳ Seamless integration across call, email, and chatbot. ↳ Handles customer interactions autonomously while ensuring human-like engagement. 2️⃣ End-to-end process management 🔄 ↳ Understands customer context, analyzes requests, gathers data, and resolves issues. ↳ Only escalates complex cases to human agents, optimizing response efficiency. 3️⃣ 24/7 multilingual support 🌍 ↳ Serves customers in multiple languages, ensuring accessibility worldwide. ↳ Provides instant, consistent, and high-quality responses every time. AI isn’t the future of customer service—it’s already here. And Yampa is leading the way. What’s your take on AI-powered customer service? Will AI agents replace human support teams, or will they enhance them? Let me know in the comments ⬇️ ♻️ Repost to keep your network updated on AI’s impact in customer service. And follow Future Techly for more insights on AI & technology.

Labviva Raises $25M to Revolutionize Life Sciences Procurement with AI Procurement in life sciences is evolving fast. And Labviva is leading the charge. The Boston-based AI-driven procurement platform just raised $25M in Series B funding to take its innovation to the next level. Here’s why this is big news ⬇️ Why Procurement Needs a Rethink Traditional procurement in life sciences is slow, fragmented, and inefficient: ➡️ Researchers waste hours comparing products manually. ➡️ Procurement teams struggle with compliance and contract rules. ➡️ Small and green-certified suppliers get overlooked. Labviva is solving these problems by connecting researchers with suppliers seamlessly—all while ensuring compliance, reducing costs, and eliminating inventory gaps. How Labviva is Changing the Game The platform aggregates 90% of all life science suppliers, offering instant access to a diverse pool—from major brands to small, sustainable businesses. It integrates directly with SAP Ariba, Oracle Procurement Cloud, Microsoft Dynamics 365, and more, ensuring smooth procurement without disrupting existing workflows. How the $25M Funding Will Accelerate Growth Led by CEO Siamak Baharloo, Labviva will use the funding to: ✅ Enhance product development. ✅ Expand marketing and customer support. ✅ Scale internationally. With backing from 53 Stations, Biospring Partners, B Capital Group, and Glasswing Ventures, Labviva is poised to redefine procurement in life sciences. And with Jason Pritzker from 53 Stations joining the board, they have the expertise to scale even faster. Procurement isn’t just about cost savings—it’s about efficiency, compliance, and accessibility. Labviva is setting a new standard for the industry. What’s your biggest challenge in procurement? Let me know in the comments ⬇️ ♻️ Repost to share this innovation with your network. And follow Future Techly for more updates.

hc1 Just Raised $6.25M to Transform Lab Data into Actionable Intelligence The future of healthcare depends on how we use data. hc1, an Indianapolis-based company, just secured $6.25M in funding to revolutionize lab data analytics. Here’s how this funding will drive change ⬇️ Healthcare is evolving, and data-driven decision-making is the key to better patient outcomes. With this investment, hc1 aims to: ➡️ Enhance lab stewardship to ensure patients receive the right tests, leading to earlier and more accurate diagnoses. ➡️ Optimize patient blood management, particularly for those with anemia, reducing costs while improving health outcomes. ➡️ Eliminate supply chain waste by leveraging AI, advanced analytics, and benchmarking to optimize staffing and resource allocation. ➡️ Drive profitable growth for health systems through efficient lab outreach and smarter decision-making. Why does this matter? Inefficiencies in lab testing, misdiagnoses, and poor resource management cost the healthcare industry billions—not to mention the impact on patient lives. That’s why hc1, under the leadership of CEO and Founder Bradley Bostic, is bringing AI-powered analytics and workflow automation to the forefront. Their goal? Uncover hidden risk signals, improve clinical and operational excellence, and maximize revenue growth across the entire care continuum. The future of healthcare isn’t about more tests—it’s about smarter tests. How do you see AI shaping the future of healthcare? Let me know in the comments ⬇️ ♻️ Repost to spread awareness about the power of AI in healthcare. And follow Future Techly for more industry insights.

Qventus, Inc Secures $105M to Transform AI-Powered Healthcare Operations AI is reshaping the future of healthcare. The question is—are we ready to embrace it? Qventus, a leading AI-based care automation provider, just raised $105M in Series D funding to expand its impact beyond Surgical Growth and Inpatient Capacity solutions. The round was led by KKR, with participation from Bessemer Venture Partners and strategic investors, including Northwestern Medicine, HonorHealth, and Allina Health. Why does this matter? AI-driven automation is no longer a luxury—it’s a necessity. Health systems face overcrowding, staff burnout, and operational inefficiencies. Qventus is solving these problems by: ➡️ Predicting bottlenecks before they happen. ➡️ Optimizing patient flow in both OR and inpatient settings. ➡️ Reducing cognitive load on care teams. ➡️ Improving the patient experience with seamless automation. By integrating with EHRs and leveraging Generative AI, machine learning, and behavioral science, Qventus empowers health systems to operate more efficiently and profitably. The impact? ✅ 36,000+ excess inpatient days eliminated—saving millions for hospitals. ✅ $95M in annualized contribution margin generated through surgical volume optimization. ✅ More patients served, less staff burnout, and greater financial stability. This $105M investment will fuel faster innovation and expansion into new care settings—helping more health systems unlock capacity and drive surgical growth. AI in healthcare isn’t the future—it’s happening now. What are your thoughts on AI-powered care automation? Drop your insights in the comments ⬇️ ♻️ Repost to keep your network updated on healthcare AI innovations. And follow Future Techly for more updates.

Normunity Just Raised $75M to Revolutionize Cancer Treatment The future of cancer treatment is changing—and Normunity is leading the way. The Boston- and New Haven-based biotech company just secured $75 million in Series B funding to advance its groundbreaking T cell engager therapy, NRM-823. Why does this matter? Normunity isn’t just developing another cancer treatment—it’s unlocking untapped biology at the intersection of the immune system and tumors. This could mean: ➡️ More effective treatments for solid tumors. ➡️ A new way to bypass immune system evasion by tumors. ➡️ A shift in how we approach anti-cancer therapy. The Breakthrough: NRM-823 Normunity’s lead program, NRM-823, is a first-in-class T cell engager designed to precisely target tumor cells without harming healthy ones. 🚀 Expected to enter the clinic in 2025, this therapy has the potential to redefine cancer treatment as we know it. The Investors Behind the Vision This $75M funding round was led by Samsara BioCapital and Enavate Sciences, alongside major players like Regeneron Ventures, Pfizer Ventures, and YK Bioventures. The company’s Board of Directors is expanding, bringing in top minds from Samsara, Enavate, and Pfizer Ventures to drive innovation forward. What’s Next? With this funding, Normunity is pushing the boundaries of cancer research, developing therapeutic antibodies, bispecific antibodies, and payload-carrying biologics to combat solid tumors. Cancer treatment is evolving. Normunity is making it happen. What do you think about this breakthrough? Drop your thoughts in the comments ⬇️ ♻️ Repost to share this innovation with your network. And follow Future Techly for more.

RhyGaze AG Secures $86M to Restore Vision Through Gene Therapy Blindness affects millions, but groundbreaking innovations are bringing hope. Here’s how RhyGaze is changing the future of vision restoration ⬇️ Gene therapy is revolutionizing the way we treat retinal diseases: ➡️ It has the potential to restore vision in patients with blindness. ➡️ It targets the root cause of genetic eye disorders, not just the symptoms. ➡️ It offers long-term solutions instead of temporary fixes. Without advancements in this field... Millions will continue to suffer from irreversible vision loss. That’s why companies like RhyGaze are leading the charge. The Basel, Switzerland- and Philadelphia, PA-based biotech company just raised $86M in Series A funding to develop optogenetic vision restoration therapies. This round was led by GV (Google Ventures), with support from ARCH Venture Partners, F-Prime Capital, BGV (BioGeneration Ventures), and Novartis Venture Fund. The funds will accelerate the clinical development of RhyGaze’s lead gene therapy candidate—a breakthrough treatment designed to restore vision in patients suffering from retinal diseases. Here’s what makes RhyGaze a game-changer: 🔬 Founded by world-class scientists – Drs. Botond Roska, Bence Gyorgy, and Charles Gubser, with CEO Dr. Katherine High at the helm. 🌍 Backed by cutting-edge research – Developed at the Institute of Molecular and Clinical Ophthalmology Basel (IOB). 💡 Driven by a mission to restore sight – Bringing hope to those living with blindness. The name RhyGaze comes from "Rhy" (the Basel-German word for the Rhein), a nod to its deep scientific roots along the riverbanks of Basel. Gene therapy isn’t just innovation—it’s a lifeline for millions. What are your thoughts on gene therapy for vision restoration? Let me know in the comments ⬇️ ♻️ Repost to spread awareness about this breakthrough. And follow Future Techly for more insights on biotech innovation.

Overhaul Just Raised $55M—Here’s Why It Matters Supply chain disruptions can cost billions. Delays, theft, and damage threaten businesses daily. That’s why Overhaul just secured $55 million in equity funding to push supply chain risk management to the next level. Here’s what this means for the future of logistics ⬇️ With this funding, Overhaul plans to: ➡️ Advance AI-driven capabilities to predict and mitigate risks faster. ➡️ Enhance customer value with real-time insights and proactive interventions. ➡️ Pursue strategic M&A to expand its global reach and technology stack. The funding round was led by Springcoast Partners, with continued support from Edison Partners and Americo. As part of the deal, Christopher Dederick and Holger Staude from Springcoast will join Overhaul’s board. Why Overhaul Stands Out Led by CEO Barry Conlon, Overhaul is redefining supply chain security with: ✅ 7 global monitoring control towers providing 24/7 cargo protection. ✅ Direct law enforcement partnerships ensuring fast recovery in case of theft. ✅ Advanced software & AI-powered monitoring to prevent delays, spoilage, and damage before they happen. Trusted by Industry Leaders Overhaul’s solutions power major enterprises across pharma, healthcare, technology, logistics, retail, and food & beverage—including Microsoft, Bristol Myers Squibb, Dyson, and CEVA Logistics. With this new funding, they’re set to push the boundaries of supply chain intelligence even further. The question is: How do you see AI shaping the future of logistics? Drop your thoughts in the comments ⬇️ ♻️ Repost to keep your network informed. And follow Future Techly for more insights.

Windward Bio Secures $200M to Revolutionize Severe Asthma Treatment Securing funding is one thing—using it to transform lives is another. Windward Bio just raised $200 million in Series A funding to push the boundaries of severe asthma treatment. 🚀 Here’s why this matters: ➡️ Severe asthma affects millions, with limited effective long-term treatment options. ➡️ WIN378, their lead drug candidate, could be a game-changer with just two doses per year. ➡️ Phase 2 trials are set to begin, with initial results expected in 2026. If successful, this could redefine respiratory care for millions of patients in the US, Europe, and Japan. Who’s backing this innovation? 🔹 Led by OrbiMed, Novo Holdings, and Blue Owl Capital Healthcare Opportunities 🔹 Supported by top investors: SR One Capital Management, Omega Funds, RTW Investments, LP, Qiming Venture Partners, Quan Capital 泉创资本, and Pivotal bioVenture Partners What makes WIN378 different? 💡 Long-acting monoclonal antibody therapy—potentially dosed only every six months 💡 Targets TSLP ligand, a key driver of inflammation in severe asthma 💡 Potential applications beyond asthma, including COPD Beyond WIN378: Windward Bio is also building a discovery pipeline of long-acting bispecifics, leveraging cutting-edge immunology research to push boundaries even further. A Leadership Team to Watch: 🧑⚕️ Luca Santarelli, MD (CEO & Founder) 🩺 David Bonita, MD (OrbiMed) 💡 Naveed Siddiqi, MD (Novo Holdings) 💰 Tim Anderson (Blue Owl Healthcare Opportunities) 📈 Iqbal Mufti (SR One) 🔬 Otello Stampacchia, PhD (Omega Funds) Windward Bio isn’t just another biotech startup—it’s on a mission to redefine immunology treatment. What are your thoughts on long-acting biologics in asthma treatment? Let’s discuss in the comments! ⬇️ ♻️ Repost to keep your network informed. And follow Future Techly for more updates on breakthrough biotech innovations.

The government hiring system is broken. It takes 135 days on average to fill a public sector role—5x longer than the private sector. And the cost? $86 billion in taxpayer-funded overtime. That’s why Holly is stepping in to fix it. Holly, an AI-powered platform modernizing government hiring, just raised $2.2M in Pre-Seed funding to accelerate its mission. ⬇️ What Holly Does Government hiring is outdated, inefficient, and costly. Holly changes that by: ➡️ Modernizing job classifications with AI. ➡️ Streamlining agency workflows to speed up hiring. ➡️ Embedding equity throughout the recruitment process. Who’s Backing Holly? The funding round was led by J2 Ventures, with participation from Roble Ventures, Gaingels, and angel investors. The Future of Government Hiring Founded in 2023 by Brendan Hellweg and Cherie Chung, Holly is building a faster, smarter, and fairer public sector hiring system. With this funding, the company will expand operations and development efforts to scale its impact. AI isn’t just transforming private sector hiring—it’s revolutionizing how governments recruit millions of people. This isn’t just about hiring faster. It’s about saving billions and making public sector jobs more accessible. What do you think—should AI play a bigger role in government hiring? Let me know in the comments ⬇️ ♻️ Repost to spread the word about fixing government hiring. And follow Future Techly for more insights on AI and technology.